Accepted for/Published in: JMIR Research Protocols
Date Submitted: Mar 18, 2020
Date Accepted: Dec 1, 2020
Uncovering the Bone-Muscle Interaction and its Implications for the Health and Function of Older Adults, the Wellderly Project: a Protocol for a Randomised, Controlled Crossover Trial
ABSTRACT
Background:
Bone and muscle are closely linked anatomically, biochemically and metabolically. Acute exercise affects both bone and muscle implying a crosstalk between the two systems. However, how these two systems communicate is still largely unknown. We will explore the role undercarboxylated osteocalcin (ucOC) in this crosstalk. ucOC is involved in glucose metabolism, with a potential role in muscle maintenance and metabolism.
Objective:
The proposed trial will determine a) if circulating ucOC levels in older adults at baseline and following acute exercise is associated with parameters of muscle function and b) if ucOC response to exercise is varied between older adults with low compared to those with normal/high muscle quality.
Methods:
Fifty-four men and women aged >60 years with no history of diabetes and not using warfarin and/or vitamin K will be recruited. Screening tests will be performed and includes functional, anthropometric and clinical presentation. Based on muscle quality, a combined equation of lean mass (leg appendicular skeletal muscle mass, kg) and strength (leg press, 1-repitition maximum), participants will be stratified into two groups (high and low muscle function) and randomised into the controlled, crossover acute intervention. Three visits will be performed ~7days apart, and in any order, acute aerobic exercise, acute resistance exercise and a control session (rest) will be completed. Our primary outcome is the effect of exercise on ucOC between people with low and high muscle function.
Results:
The trial is active and ongoing. Recruitment began in February 2018 with 38 participants complete as of 26th May 2019.
Conclusions:
This study will provide novel insights into bone and muscle crosstalk in older adults and potentially identify new clinical biomarkers and mechanistic targets for drug treatments for sarcopenia and other related musculoskeletal conditions. Clinical Trial: Australia New Zealand Clinical Trials Registry (ref. ACTRN12618001756213). Registered 25 October 2018– retrospectively registered, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375925
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.